Core Insights - The article highlights the significant health benefits of the star oil vine (美藤果), particularly its effectiveness in lowering uric acid levels, blood lipids, and blood pressure, as well as its potential in alleviating dry eye syndrome and Alzheimer's disease [1][2][3]. Group 1: Health Benefits - The star oil vine is recognized for its diverse medicinal properties, with its fruit kernels being a key source of value due to their high unsaturated fatty acid and quality protein content [7][8]. - The unsaturated fatty acids in the fruit exhibit strong health benefits, effectively lowering blood lipids and improving conditions such as dry eye syndrome and dermatitis, with initial positive effects noted for Alzheimer's disease [8][9]. - The protein content in the fruit is notably high, particularly in albumin, which is rich in sulfur amino acids, making it suitable for use in sports drinks and protein supplements, significantly enhancing immune function [10][12]. Group 2: Research and Development - The research team led by Professor Du Bing has published 16 SCI papers and 48 Chinese papers, establishing a leading position in the study of the star oil vine [14]. - The team has developed a preparation technology for star oil vine peptides, identifying their structure and obtaining a patent, with a notable discovery of the peptides' excellent uric acid-lowering capabilities [15][16]. Group 3: Innovative Formulations - The combination of dried tangerine peel (陈皮) with star oil vine has shown remarkable synergistic effects, enhancing both the taste and efficacy of the oil [21][22]. - The innovative formulation of tangerine peel oil, star oil vine oil, and lutein has demonstrated a superior effect in improving dry eye syndrome, achieving a "1+1+1 > 3" outcome [23][24].

"鹿角结石具有隐匿进展、急性发作的特点。"邓远忠说，针对"熊猫血"配血难题，医生在术前为许 先生进行了自体血液储备。经过一周的抗感染治疗，二次手术将剩余的结石完全粉碎清除。第二次手术 后仅两天，许先生顺利康复出院。出院前复查显示，其左肾结石已基本清除，肾功能稳定。 邓远忠提醒，夏季天气炎热，人体出汗多，体内水分流失快，尿液浓缩后，矿物质变成细小坚硬的 沉积物，容易形成结石。对此，他提出建议： 夏季气温攀升，高温下出汗量增加，水分补充不足，尿液易过度浓缩，肾结石进入高发期。重庆医 科大学附属第一医院泌尿外科主任医师邓远忠27日告诉记者，预防肾结石，关键是阻断"感染—结晶"链 条，需多维度干预。 "我们医院泌尿外科肾结石患者近期明显增加。"邓远忠介绍，不久前，前来就诊的"熊猫血"(Rh阴 性血型)男子许先生，肾结石竟有9厘米长。 今年55岁的许先生在约20年前就发现有肾结石，曾做过一次肾结石手术，平时没太把该病放在心 上。今年年初，熟悉的左侧腰痛再次袭来，在外地上班的他前往医院检查，结果把他吓了一跳：左肾被 巨大鹿角结石完全填塞，严重损害肾功能。许先生听到消息后，赶紧回到老家重庆，前往重医附一院就 诊。 二是建议 ...

一个高血糖的人，全身器官就像"泡"在糖水里：血管、心脑、眼睛、免疫……都在一点点被侵蚀。 2025年6月，中国疾病预防控制中心慢病中心发布了最新版糖尿病流行的"中国图谱"：2023年全国糖尿病患者数量已达2.33亿，占全球糖尿病人口的四分 之一。 糖尿病患者数量激增至2.33亿 最新数据显示，我国糖尿病患者人数达2.33亿，相当于每6个人里就有1个患病者。与2005年相比，糖尿病患者数量激增了163%。 性别分析显示，男性糖尿病流行率始终高于女性；吸烟、肥胖以及社会文化和生物学因素都是导致这一差异的重要原因。 褶皱处皮肤颜色变黑 颈部、腋下、腹股沟等皮肤褶皱处颜色加深，表面变得粗糙，类似天鹅绒的触感。 这是胰岛素抵抗引起的黑棘皮病，是糖尿病前期或已确诊糖尿病患者中常见的皮肤表现。 出现皮赘 皮肤上出现的小肉球或息肉状增生物，多见颈部、腋窝、腹股沟等区域，通常是良性的。专家表示，高血糖患者由于代谢紊乱，很容易出现这类皮肤问 题。 在地域分布中，北京以28.45%的患病率位居榜首，天津和上海分别以25.78%和22.04%位列第二和第三；浙江、福建、新疆也位居前列。 总体来说，华北地区糖尿病流行率最高，其次是东北 ...

Core Insights - BrightGene Pharmaceutical Co., Ltd. presented promising Phase II clinical trial data for its dual-target agonist BGM0504 at the 85th American Diabetes Association (ADA) Scientific Sessions, indicating potential advantages over Semaglutide in treating type 2 diabetes and obesity [1][4] - The company also shared preclinical results for a new Amylin, BGM1812, which shows enhanced receptor activation and potential for effective weight management [1][5] Group 1: BGM0504 Clinical Data - BGM0504 demonstrated significant reductions in HbA1c, fasting blood glucose, postprandial blood glucose, weight, and blood pressure in adult patients with type 2 diabetes during Phase II trials [3][4] - The majority of adverse events were mild to moderate and resolved without intervention, with no observed cases of hypoglycemia or unexpected adverse events, indicating a favorable risk-benefit profile [3][4] - The drug is currently undergoing Phase III clinical trials in China for weight management and type 2 diabetes, with over 1,000 patients treated, showing excellent efficacy and safety [4] Group 2: BGM1812 Development - BGM1812 is a novel Amylin designed using AI/ML optimization, characterized by strong and prolonged effects, with potential for development into a weekly oral formulation [5] - The company aims to leverage its expertise in peptide development to accelerate innovative therapies for unmet clinical needs in metabolic diseases [4]

专家建议，预防糖尿病足，糖尿病患者每日需用38℃以下温水泡脚，擦干后检查趾间有无破损，穿 透气棉 袜与宽松鞋，并每年至少做一次足部血管神经专项检查。 国际糖尿病联盟最新数据显示，我国20—79岁糖尿病患者人数到2030年预计将突破1.64亿人。随着 糖尿病患病率的持续攀升，糖尿病足这一严重并发症的患病人数也呈逐年递增趋势。临床统计表明，我 国50岁以上糖尿病患者中，糖尿病足1年新发率达8.1%，总截肢率高达19.3%。 令人振奋的是，广州医科大学与中国科学院联合团队近期通过基因工程改造干细胞技术，实现实验 室环境下14天内糖尿病足伤口愈合率超96%，为众多患者带来希望。与此同时，抗生素骨水泥、脊髓电 刺激器植入术（SCS）、血管重建与修复等治疗技术也取得突破性进展，为糖尿病足的临床干预开辟了 新路径。 血糖失控渐进性破坏足部组织 "糖尿病是一种表现为血糖异常升高的代谢性疾病。糖尿病对双足的影响，本质是高血糖引发的'血 管—神经—免疫'三重打击。"天津医科大学第二医院手足显微外科副主任医师苗平指出，糖尿病足的发 生、发展背后是血糖失控对足部组织的渐进性破坏。 多项突破为解决临床难题带来希望 糖尿病足作为糖尿病最 ...

智通财经6月23日电，礼来6月22日宣布了QWINT-1、QWINT-3和QWINT-4三项3期临床研究的详细结 果。这些研究分别评估了每周一次胰岛素efsitora alfa（efsitora）在首次使用胰岛素治疗、既往已使用每 日基础胰岛素治疗，以及既往基础胰岛素与餐时胰岛素联用的2型糖尿病（T2DM）成人患者中的有效 性和安全性。所有研究中均达到了主要终点，即每周一次的efsitora在降低糖化血红蛋白（A1C）水平方 面非劣效于每日一次基础胰岛素。礼来计划于今年年底前向全球监管机构递交efsitora用于治疗2型糖尿 病成人患者的上市申请。 礼来计划年底前递交efsitora用于治疗2型糖尿病成人患者的上市申请 ...

整理 | GLP1减重宝典内容团队 在2022年国际糖尿病联盟（IDF）大会上，首次以墙报形式展示了PIONEER 11和PIONEER 12研究的结果。这两项研究以中国人群为 主，为司美格鲁肽片（商品名：诺和忻）在中国的获批提供了重要支持。该药物的治疗剂量为7mg或14mg，适用于在饮食和运动控制 不足的基础上，作为单药或与二甲双胍和/或磺脲类药物联合治疗的成人2型糖尿病（T2DM）患者。 与欧美人群不同，中国的2型糖尿病患者通常在较年轻时就被诊断，且BMI较低，这可能影响药物的治疗效果，因此中国研究是必要 的。 在中国人群中，司美格鲁肽片的疗效和安全性数据相对较少，PIONEER 11和12研究则为该领域提供了重要的临床数据。 PIONEER系列的全球3期临床试验比较了司美格鲁肽片与活性对照药物及安慰剂在降糖效果和安全性上的差异，以及体重的减轻，结果 显示，司美格鲁肽片能够持续改善血糖控制以及减重，且效果优于活性对照药物和安慰剂。 ▍PIONEER 11 单药治疗 PIONEER 11研究在饮食和运动控制不佳的中国2型糖尿病患者中，评估了司美格鲁肽片单药治疗的有效性与安全性。研究结果显示， 中国 人群的临 ...

一项研究发现，早上8点之前吃第一顿饭、晚上7点之前吃最后一餐，更有助于降低2型糖尿病的发病率。而如果晚餐较晚才吃会增加2型糖尿病的风险。 2022年《糖尿病护理》期刊发表的一项研究显示：晚餐吃得晚，对血糖不友好。实验发现：晚餐吃得太晚会导致胰岛素降低6.7%，葡萄糖升高8.3%。简单 来说，晚餐时间越晚，血糖水平越高。 当前我国成年人糖尿病患病率总体呈升高趋势。缺乏运动、常喝甜饮料、吃晚饭时间太晚……我们的日常生活习惯，跟糖尿病有着极大的关联。这8个习 惯，让人不知不觉患上糖尿病↓ 习惯一：吃晚饭时间太晚 你几点吃晚饭？ 对大多数人来说，早点吃晚饭，让自己在睡前4小时内不吃东西，是避免糖尿病的明智选择。 习惯二：日常吃红肉太多 猪肉、羊肉、牛肉，你更喜欢吃哪个？ 如今，越来越多研究发现，日常红肉（猪肉、羊肉、牛肉）吃得太多会增加糖尿病的风险！ 一项研究发现：每周只摄入2份红肉的人群或许相比少吃红肉的人群患2型糖尿病的风险更高，而且这一风险会随着红肉摄入量的增加而增加。 你爱喝甜饮料吗？你身边有把甜饮料当水喝的人吗？ 一项研究发现：喝含糖饮料、人工甜味剂（代糖）饮料或增加糖尿病风险。与很少喝甜饮料的人相比，每天 ...

整理 | GLP1减重宝典内容团队 ▍胰岛素抵抗的定义及其代谢危害 《胰岛素抵抗评估方法及应用专家指南》指出，胰岛素抵抗（insulin resistance, IR）是指当胰岛素不能有效刺激外周组织摄取葡萄糖并抑制肝 脏葡萄糖输出时的状态。其不仅是2型糖尿病（T2DM）发生发展的核心机制之一，还与多种代谢紊乱及心血管疾病密切相关。 脂联素水平下降：这一胰岛素敏感性激素降低，也会削弱对胰岛素的反应性。 ▍司美格鲁肽改善胰岛素抵抗的多机制作用 司美格鲁肽是一种胰高血糖素样肽-1受体激动剂（GLP-1RA），不仅用于控制血糖，其对胰岛素抵抗的改善也具有多靶点、多层面优势： 一项针对2569名非糖尿病受试者的前瞻性研究发现，随着基线HOMA-IR（胰岛素抵抗评估指标）五分位数的升高，血清甘油三酯、收缩压和 舒张压水平均升高，而高密度脂蛋白胆固醇水平则下降， 说明胰岛素抵抗与代谢健康水平呈显著负相关关系。 在T2DM人群中，一项包含1326名患者的研究指出，HOMA-IR每增加1个单位，心血管事件的风险将增加56%。美国NHANES数据模拟结果进 一步证实，改善胰岛素抵抗可使心肌梗死的风险下降42%。 ▍胰岛素抵抗的 ...

Vertex Pharmaceuticals (VRTX) Conference Summary Company Overview - **Company**: Vertex Pharmaceuticals - **Event**: Conference at the American Diabetes Association 85th Scientific Sessions - **Date**: June 20, 2025 Key Industry and Company Insights Type 1 Diabetes (T1D) Landscape - T1D is caused by the destruction of insulin-producing beta cells in the pancreas, leading to a lifelong dependency on insulin therapy, which has not significantly changed since 1921 [7][9] - Approximately 4 million people are diagnosed with T1D in North America and Europe, with an estimated 60,000 patients experiencing severe hypoglycemic events [11][42] - Severe hypoglycemic events can lead to serious complications, including seizures and increased mortality rates, with those affected having a fivefold increased risk of death [12] Zamyla Cell Overview - **Zamyla Cell**: An investigational islet cell therapy derived from stem cells, designed to replace destroyed islet cells in T1D patients [13] - Administered via infusion into the hepatic portal vein, protected from immune destruction through a steroid-free immunosuppressive regimen [14] - The pivotal Phase 1/2/3 study is progressing, with enrollment expected to complete in summer 2025 [15] Clinical Trial Data - The FORWARD study has transitioned to a Phase 3 pivotal study, focusing on patients with severe hypoglycemia and impaired awareness [20] - Primary efficacy endpoints include freedom from severe hypoglycemia and achieving a hemoglobin A1c (HbA1c) of less than 7% [20] - Data from 12 participants showed restored endogenous insulin production and significant reductions in HbA1c, with 10 out of 12 participants eliminating insulin requirements by 12 months [23][25] Regulatory and Market Potential - Vertex has received several regulatory designations, including RMAT and fast track designations in the US, and PRIME designation in Europe, highlighting the high unmet need for T1D therapies [15] - Anticipated regulatory submissions for Zamyla Cell are expected in 2026, with preparations for commercialization underway [42] Additional Insights Patient Population and Treatment Considerations - Ideal candidates for Zamyla Cell therapy are adults with long-standing T1D and impaired awareness of hypoglycemia [64] - The therapy is expected to significantly improve the quality of life for patients, addressing the burdens of daily diabetes management [39] Future Innovations - Vertex is exploring next-generation therapies, including gene editing and novel immunotherapies, to enhance treatment options for T1D [60] - Manufacturing capabilities are being expanded to meet anticipated demand, with partnerships established to support production [61] Challenges and Considerations - Continuous glucose monitoring has reduced severe hypoglycemic events, but a significant portion of patients still experience these events, indicating a continued need for therapies like Zamyla Cell [49] - The potential for redosing Zamyla Cell exists, as it is an off-the-shelf therapy that can be supplied on demand [54] Conclusion - Zamyla Cell represents a transformative potential for T1D treatment, addressing a significant unmet medical need for patients suffering from severe hypoglycemia [42] - Vertex Pharmaceuticals is positioned to lead advancements in T1D therapies, with ongoing research and development efforts aimed at improving patient outcomes and quality of life [60]